4D Molecular Therapeutics, Inc. FDMT

14.47 (0.24) (1.63%) as of 25 Sep
Market cap
$807.1M
P/E
0.0×

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Net Income
(179.17) (160.90) (140.11) (209.18)

+8 more TTM periods

Depreciation & Amortization
0.60 0.31 (0.04) (0.86)
Non Cash Items (Other)
23.60 22.55 24.90 26.85
Accounts Payable Change
1.93 10.54 6.77 3.94
Change in payables and accrued liability
9.78 6.34 8.15 3.41
Change in other assets and liabilities
(12.81) (8.29) (8.75) (7.65)
Operating Cash Flow
(156.07) (129.45) (109.08) (183.50)
Capital expenditures
0.11 0.11 (0.54) (1.55)
Long-Term Investments Change (Net)
(16.74) (56.14) (92.44) 44.49
Investing cash flow
(16.64) (56.03) (92.97) 42.93
Equity Repurchase (Common, Net)
72.38 30.90 20.02 2.15
Equity Repurchase (Preffered, Net)
— — 166.01 —
Financing cash flow
165.92 124.44 113.56 2.15
Change in Cash
(6.79) (61.04) (89.09) (138.98)
Beginning Cash
60.24 60.24 149.34 149.34
Ending Cash
53.45 (0.80) 60.24 10.35
Stock Based Compensation
20.41 19.48 22.02 24.04
Dividends Paid (Common)
0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
(1.10) 8.59 6.17 (0.30)
Investments Change (Net)
(16.74) (56.14) (92.44) 44.49
Issuance/Purchase of Shares
165.92 124.44 113.56 2.15

Fold the line items

In millions of $ except per-share values · columns are period end dates